Home › Non-Small Cell Lung Cancer › California
Non-Small Cell Lung Cancer clinical trials in California
207 studies for Non-Small Cell Lung Cancer are looking for participants at sites in California.
Cities in California
- Los Angeles87 studies
- San Diego48 studies
- Santa Monica45 studies
- Baldwin Park36 studies
- San Francisco36 studies
- Sacramento29 studies
- Irvine25 studies
- Orange25 studies
- Mountain View21 studies
- Santa Rosa17 studies
- Huntington Beach14 studies
- Concord14 studies
- Newport Beach14 studies
- Fullerton13 studies
- Long Beach12 studies
- Torrance11 studies
- Vallejo10 studies
- Roseville10 studies
- San Bernardino9 studies
- Glendale9 studies
- Anaheim8 studies
- Westminster8 studies
- Modesto7 studies
- San Jose7 studies
- Fresno7 studies
- Richmond7 studies
- Burbank6 studies
- Oakland6 studies
- Santa Clara6 studies
- Fremont6 studies
- Stockton6 studies
- Santa Barbara5 studies
- Daly City5 studies
- Berkeley5 studies
- San Leandro5 studies
- Sunnyvale5 studies
- Oxnard5 studies
- Lancaster4 studies
- San Mateo4 studies
- Riverside3 studies
- Yuba City3 studies
- Pleasanton3 studies
- Santa Maria3 studies
- Salinas3 studies
- Clovis3 studies
- Redwood City3 studies
- Norwalk3 studies
- Upland3 studies
- Indio3 studies
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Kaiser Permanente-Anaheim, Anaheim
- Kaiser Permanente-Deer Valley Medical Center, Antioch
- Sutter Auburn Faith Hospital, Auburn
- and 56 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT04267848A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Providence St. Jude Medical Center ( Site 0106), Fullerton
- VA Long Beach Healthcare System ( Site 0199), Long Beach
- USC Norris Comprehensive Cancer Center ( Site 0205), Los Angeles
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06623422Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
- Clinical Research Advisors, LLC, Beverly Hills
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06472245A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
- USC / Norris Comprehensive Cancer Center, Los Angeles
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07293247The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- University of San Diego Moores Cancer Center, La Jolla
- UCLA Jonsson Comprehensive Cancer Center, Los Angeles
- USC Norris Comprehensive Cancer Center, Los Angeles
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 2, 2026 · NCT04585750A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- City of Hope National Medical Center, Duarte
- University of California, San Diego (UCSD) - Moores Cancer Center, La Jolla
- UCLA Department of Medicine-Hematology/Oncology, Los Angeles
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06465069A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
- Los Angeles Cancer Network, Glendale
- Providence St. Joseph Hospital, Orange
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07365319Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #59, Santa Barbara
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT05176483A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
- UC Davis Comprehensive Cancer Center ( Site 3204), Sacramento
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07513376A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- City of Hope, Duarte
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06172478A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- City of Hope National Medical Center, Duarte
- City of Hope at Irvine Lennar, Irvine
- Ronald Reagan UCLA Medical Center, Los Angeles
- and 3 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07090499Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
- Tower Cancer Research Foundation, Beverly Hills
- Cedars-Sinai Medical Center, Los Angeles
- Cedars-Sinai Cancer - Tarzana, Tarzana
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07388524A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- City of Hope National Medical Center /ID# 277005, Duarte
- City of Hope - Orange County Lennar Foundation Cancer Center /ID# 277928, Irvine
- UC San Diego Health - Moores Cancer Center /ID# 278836, La Jolla
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07155187Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- City of Hope Comprehensive Cancer Center, Duarte
- University of California Los Angeles, Los Angeles
- University of California San Diego Moores Cancer Center, San Diego
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06625775Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Tower Cancer Research Foundation, Beverly Hills
- Kaiser Permanente Dublin, Dublin
- Kaiser Permanente-Fremont, Fremont
- and 20 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06498635A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
- Research Site, Santa Rosa
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06996782A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
- ALX Center 9, La Jolla
- ALX Center 11, Santa Monica
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07085091Adaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC
- Stanford University, Stanford
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT04585490A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
- Beverly Hills Cancer Center, Beverly Hills
- Orange Coast Memorial Medical Center, Fountain Valley
- Local Institution - 0027, Los Alamitos
- and 5 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07361510A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
- START LA, Los Angeles
- Cedars-Sinai Medical Center, Los Angeles
- Valkyrie Clinical Trials, Los Angeles
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07659782Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
- Hoag Hospital Newport Beach, Newport Beach
- University of California, Irvine Health, Orange
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT06765109A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Research Site, Duarte
- Research Site, Los Angeles
- Research Site, Newport Beach
- and 1 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT05877599Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
- Providence - St. Jude Medical Center /ID# 271414, Fullerton
- FOMAT Medical Research - Clinica mi Salud by Focil Med /ID# 274450, Oxnard
- UCLA - Santa Monica /ID# 271690, Santa Monica
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT06772623Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
- MemorialCare Long Beach Medical Center, Long Beach
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT06881784A Study of PHN-012 in Patients With Advanced Solid Tumors
- PHN-012-001 Site, Los Angeles
- PHN-012-001 Site, San Diego
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07127874A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Alta Bates Summit Medical Center Comprehensive Cancer Center, Berkeley
- John Muir Health Clinical Research Center, Concord
- UC San Diego Medical Center - Encinitas, Encinitas
- and 16 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07144280A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
- University of California at San Diego, La Jolla
- University of California Irvine, Orange
- Stanford Cancer Institute, Stanford
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05498428A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
- City of Hope, Duarte
- City of Hope 1, Irvine
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07586202A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Beverly Hills Cancer Center ( Site 0070), Beverly Hills
- UCLA Clinical & Translational Research Center (CTRC) ( Site 0033), Los Angeles
- Hoag Memorial Hospital Presbyterian ( Site 0096), Newport Beach
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06312137Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Oncura Health - Anaheim, Anaheim
- Memorial Care Orange Coast Medical Center Attn, Fountain Valley
- MemorialCare Orange Coast Medical Center, Fountain Valley
- and 20 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07222566A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Sansum Clinic, Santa Barbara
RecruitingPhase 3
Ages 18 to 100 · All sexes · Updated Sep 25, 2026 · NCT05920356Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
- Research Site, Duarte
- Research Site, Los Angeles
- Research Site, Newport Beach
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06218914Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
- Stanford Cancer Institute, Stanford
- Stanford Hospital and Clinics, Stanford
- Stanford Hospital Investigational Drug Services, Stanford
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07489066Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- University of California San Diego, La Jolla
- Stanford University, Palo Alto
- UCLA Medical Center, Santa Monica
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT04981119This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Providence Medical Foundation, Fullerton
- Providence St. Jude Medical Center Virginia K. Crosson Cancer Center and Infusion Center, Fullerton
- Providence St. Jude Medical Center, Fullerton
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06758401A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- The Oncology Institute of Hope and Innovation, Cerritos
- City of Hope Corona, Corona
- City of Hope, Duarte
- and 26 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06667076A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
- The City of Hope Orange County Lennar Foundation Cancer Center, Irvine
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07154290A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
- Moores Cancer Center at UC San Diego Health, La Jolla
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06667908Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
- Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center ( Site 0130), Burbank
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06170788Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
- Providence Medical Foundation, Fullerton
- Providence St. Jude Medical Center - Virginia K. Crosson Cancer Center and Infusion Center, Fullerton
- Providence St. Jude Medical Center, Fullerton
- and 9 more
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07227298From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.